干扰素-α联合拉米夫定治疗慢性乙型肝炎临床疗效分析

Efficacy of interferon-α combined with lamivndine in the treatment of chronic hepatitis B

目的:分析干扰素-α联合拉米夫定治疗慢性乙型肝炎(CHB)的临床疗效。方法:将63例慢性乙型肝炎随机分为3组:干扰素组18例、拉米夫定组21例和干扰素联合拉米夫定组24例(联合治疗组),疗程均为6个月。观察疗程结束后患者病毒学和血清学变化情况及不良反应。结果:联合治疗组HBV-DNA阴转率高于干扰素组,HBeAg阴转率和抗-HBe阳转率均高于拉米夫定组,ALT复常率高于干扰素组和拉米夫定组,各组不良反应发生率无显著差异。结论:干扰素α与拉米夫定联合应用可提高慢性乙型肝炎的疗效,二者具有明显的抑制病毒复制的协同作用,值得临床推广应用。

Objective：To study the efficacy of interferon-α combined with lamivudine in the treatment of chronic hepatitis B. Methods：63 patients with chronic hepatitis B were divided into three groups which were comparable. 18 patients were treated with IFN α for about 6 months （IFN-α group）, 21 patients were treated with lamivudine （lamivudine group）,and the last 24 patients were treated with IFN-α and lamivudine（combined group）. The contents of serum ALT, HBV-DNA, HBV-Marks were detected. The side-effects were investigated. Results：The seroconversion rate of HBV-DNA in combined group was higher than that in IFN group,and the seroconversion rate of HBeAg and the seroconversion rate of anti-HBe were higher than those in the larnivudine group,the rate of returning to normal of ALT was higher than that in the other two groups. The occurrence rate of side-effects had not difference among three groups. Conclusion：IFN-α combined with lamivudlne is more effective for treating the patients with chronic hepatitis B than IFN-α or lamivudine alone.